XML 24 R8.htm IDEA: XBRL DOCUMENT v3.25.4
CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
OPERATING CASH FLOW      
Net earnings (loss) $ (62,000) $ 2,084,000 $ 79,000
Adjustments to reconcile net earnings (loss) to operating cash flow:      
Equity method earnings, net of taxes (302,000) (1,729,000) 0
Depreciation and amortization 68,000 73,000 74,000
(Gain) loss on sales of assets (7,000) (14,000) 150,000
Stock-based compensation 30,000 31,000 48,000
Deferred taxes (511,000) 42,000 (13,000)
Changes in assets and liabilities 402,000 347,000 (114,000)
Other (5,000) (6,000) (12,000)
Operating cash flow [1] (387,000) 828,000 212,000
INVESTING CASH FLOW      
Gain on the fair value of the forward sale contract of NuScale shares 605,000 0 0
Purchases of marketable securities (146,000) (205,000) (426,000)
Proceeds from sales and maturities of marketable securities 221,000 145,000 285,000
Capital expenditures (50,000) (164,000) (106,000)
NuScale cash deconsolidated 0 (131,000) 0
Proceeds from sales of assets (net of cash divested) 63,000 82,000 (5,000)
Investments in partnerships and joint ventures (278,000) (93,000) (33,000)
Return of capital from partnerships and joint ventures 22,000 34,000 8,000
Other 0 (1,000) 0
Investing cash flow 437,000 (333,000) (277,000)
FINANCING CASH FLOW      
Repurchase of common stock (754,000) (125,000) 0
Proceeds from issuance of 2029 Notes, net of issuance costs 0 0 560,000
Capped call transactions related to 2029 Notes 0 0 (73,000)
Purchases and retirement of debt (37,000) (57,000) (249,000)
Proceeds from NuScale share issuance (net of issuance fees) 0 80,000 0
Dividends paid on CPS 0 0 (29,000)
Make-whole payment on conversion of CPS 0 0 (27,000)
Distributions paid to NCI (64,000) (14,000) (53,000)
Capital contributions by NCI 65,000 0 10,000
Other (7,000) 0 (12,000)
Financing cash flow (797,000) (116,000) 127,000
Effect of exchange rate changes on cash 53,000 (69,000) 18,000
Increase (decrease) in cash and cash equivalents (694,000) 310,000 80,000
Cash and cash equivalents at beginning of year 2,829,000 2,519,000 2,439,000
Cash and cash equivalents at end of year $ 2,135,000 $ 2,829,000 $ 2,519,000
[1] Operating cash flow in 2025 included a payment of $642 million to Santos, net of insurance recoveries, for a judgment related to a reimbursable project completed by us in 2015.